From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
Already have an account? Sign in.
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
Evercore lifts Expedia’s PT to $430 (from $375); Wedbush raises its target to $417 (from $334) following the Q2 earnings beat and raised guidance.
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
Visa flags Hims for high dispute rates on $39-to-$149 weight-loss memberships. Company faces fees, scrutiny, and must lower rate for 3 months.